Your Metabolic Health and Your Risk of Cancer
Research is beginning to reveal that the metabolic health problems often associated with being or obese can themselves influence risk for certain cancers.
Progress Against Cancer
Research is beginning to reveal that the metabolic health problems often associated with being or obese can themselves influence risk for certain cancers.
The FDA's approval of a targeted therapeutic called lenvatinib provides another option for patients certain forms of thyroid cancer.
The FDA has approved of a treatment for Waldenström's macroglobulinemia, a rare form of non-Hodgkin lymphoma. Learn more.
Drinking about four cups of coffee a day appears to reduce the risk of developing endometrial cancer, a British study reports. Women who drank about four cups of coffee per day appeared to have...
The FDA recently approved new therapeutics for acute lymphoblastic leukemia, metastatic melanoma, and advanced ovarian cancer. In December 2014, the U.S. Food and Drug Administration (FDA) issued three approvals for new medications to treat...
The FDA recently approved a new HPV vaccine that could prevent up to 90 percent of cervical cancers in the U.S. In late 2014, the U.S. Food and Drug Administration (FDA) announced the approval...
A new study finds that physical activity lowers the likelihood of death in men with localized prostate cancer. Physical activity significantly lowers the risk of death from prostate cancer that has not spread from...
Lowering dietary fat intake reduced death rates in a subgroup of women with breast cancer who were part of the Women’s Intervention Nutrition Study (WINS). You know your diet is an important component of...
The promise and potential of immunotherapy to treat advanced cancers is generating excitement throughout the cancer research and cancer care community.
Despite research-driven progress against breast cancer for many, outcomes vary among women of different races and ethnicities.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More